Sodium valproate 200 mg gastro-resistant tablets ( DrugBank: Valproate )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 233 | Wolfram syndrome | 1 |
233. Wolfram syndrome
Clinical trials : 9 / Drugs : 15 - (DrugBank : 7) / Drug target genes : 11 - Drug target pathways : 41
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2017-001215-37-PL (EUCTR) | 13/02/2020 | 10/10/2019 | Clinical Trial of a Treatment to Slow Disease Progression Compared to Usual Standard of Care in Children and Adults with Wolfram | A pivotal, international, randomised, double-blind, efficacy and safety trial of sodium valporate in paediatric and adult patients with Wolfram Syndrome - Treat Wolfram | Wolfram syndrome;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Sodium valproate 200 mg gastro-resistant tablets | University of Birmingham | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 70 | Phase 2 | France;Poland;United Kingdom |